New progression of lobaplatin in the treatment of gynecologic cancer

doi:10.3760/cma.j.issn.1673-422X.2014.11.015

Abstract

Abstract: Lobaplatin is the third generation platinum anticancer drug, and has been listed for the clinical treatment of advanced breast cancer, small cell lung cancer and chronic myeloid leukemia. Studies have shown that lobaplatin as the latest third generation platinum anticancer drug, has good water solubility, broadspectrum antitumor, strong antitumor activity, no crossresistance with other platinum drugs, low toxicity and many other features. Lobaplatin has shown a clear advantage.

Key words: Lobaplatin, Genital neoplasms, female, Drug therapy

YANG Zhi-Min, LIN Yuan, CHEN Jia-Yi, WANG Hua-Ying. New progression of lobaplatin in the treatment of gynecologic cancer[J]. Journal of International Oncology, 2014, 41(11): 848-851.

References

［1］ Mc Keage MJ. Lobaplatin: a new antitumour platinum drug［J］. Expert Opin Investig Druds, 2001, 10(1):119128. ［2］ Wu Q, Qin SK, Teng FM, et al. Lobaplatin arrests cell cycle progression in human hepatocellular carcinoma cells［J］. J Hematol Oncol, 2010， 3:43. ［3］史健, 袁志芳, 刘伟娜，等. 国产注射用洛铂在恶性肿瘤患者体内药动学的研究［J］. 中国药学杂志, 2007, 42(24):18881891. ［4］叶静, 陆友金, 赵卉. 洛铂联合依托泊苷治疗小细胞肺癌的临床疗效［J］. 临床肺科杂志, 2013, 18(9): 16411643. ［5］ Xie CY, Xu YP, Jin W, et al. Antitumor activity of lobaplatin alone or in combination with antitubulin agents in nonsmallcell lung cancer［J］. Anticancer Drugs, 2012, 23(7):698705. ［6］ Shi M, Lu LG, Fang WQ, et al. roles Played by chemolipiodolization and embolization in chemoembolization for Hepatocellular carcinoma: SingleBlind, randomized trial［J］. J Natl Cancer Inst， 2013, 105(1):5968. ［7］ Deng QQ, Huang XE, Ye LH, et al. Phase Ⅱ trial of luobo and pemetrexed for pationts with metastatic breast cancer not responding to anthraycline or taxanes［J］. Asian Pac J Cancer Prev, 2013, 14(1): 413417. ［8］向燕群, 夏伟雄, 孙旭, 等. 洛铂对头颈鳞状细胞癌细胞株增殖抑制作用的体外研究［J］. 国际肿瘤学杂志, 2013, 40(6): 479481. ［9］ Long GX, Lin JW, Liu DB, et al. Singlearm, multicentre phase II study of lobaplatin combined with docetaxel for recurrent and metastatic nasopharyngeal carcinoma patients ［J］. Oral Oncol, 2014, 50(8): 717720. ［10］王辉, 段爱红, 司军英. 洛铂对SKOV3细胞凋亡及bax bcl2基因表达的影响［J］. 中国热带医学, 2010, 10(1):6870. ［11］段爱红, 王辉, 成艳梅，等. 洛铂与顺铂对卵巢癌细胞抑制作用的对照研究［J］. 中国热带医学, 2010, 10(5):625625,631. ［12］秦晓黎, 金平, 靳荣, 等. 顺铂耐药卵巢癌细胞化疗敏感性实验［J］. 中山大学学报(医学科学版), 2009, 30(1):8287. ［13］ Gietema JA, Veldhuis GJ, Guchelaar HJ, et al. Phase Ⅱ and pharmacokinetic study of lobaplatin in patients with relapsed pvarian cancer［J］. Br J Cancer, 1995, 71(6): 13021307. ［14］房玮, 王明道, 吴红卫, 等. 洛铂联合紫杉醇方案治疗卵巢癌疗效观察［J］. 中国冶金工业医学杂志, 2012, 29(2):211212. ［15］林淑君, 许慎, 蔡友鹏, 等. 洛铂联合化疗治疗复发性卵巢癌的临床观察［J］. 当代医学, 2011, 17(6):65. ［16］何海新, 林安, 李玲, 等. 晚期上皮性卵巢癌新辅助化疗中洛铂和顺铂腹腔灌注近期疗效的比较分析［J］. 福建医药杂志, 2011, 33(5):108110. ［17］任立新, 王亚帝. 紫杉醇联合洛铂或顺铂治疗晚期老年卵巢癌的疗效和安全性［J］. 中国老年学杂志, 2013, 33(10):22842286. ［18］吴坚文, 杜志强, 李丹, 等. 洛铂联合多西他赛治疗复发转移性卵巢癌的疗效［J］. 广东医学杂志, 2013, 34(6):944946. ［19］高玉玲, 宋保志. 宫颈癌新辅助化疗的临床观察［J］. 海峡药学, 2010, 22(12): 257258. ［20］刘志杰, 周军, 李妍芹. 洛铂联合氟尿嘧啶新辅助化疗治疗宫颈癌68例［J］. 中国中医药现代远程教育, 2012, 10(15):132133. ［21］ Green JA, Kirwan JM, Ierney JF, et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and metaanalysis［J］. Lancet, 2001, 358(9284):781786.

[1]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[2]	Yue Hongyun, Zhang Baihong. Differentiation therapies in human cancers [J]. Journal of International Oncology, 2024, 51(2): 109-113.
[3]	Jin Xudong, Chen Zhongjian, Mao Weimin. Research progress on the role of MTAP in malignant mesothelioma [J]. Journal of International Oncology, 2024, 51(2): 99-104.
[4]	Li Chenxi, Zhao Hongwei. Prognosis and influencing factors of platinum sensitive recurrent ovarian cancer treated by secondary cytoreduction surgery in patients with unsatisfactory primary cytoreduction surgery [J]. Journal of International Oncology, 2023, 50(6): 342-347.
[5]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer [J]. Journal of International Oncology, 2023, 50(6): 362-367.
[6]	Chen Yi, Han Liang, Cai Li. Multivariate analysis of chemotherapy induced oral mucositis in patients with head and neck tumors [J]. Journal of International Oncology, 2022, 49(9): 521-525.
[7]	Chu Xuelei, Mao Yun, Xue Peng, Li Linlu, Chen Meichi, Yuan Chunsheng, Qin Xiaoyan, Zhu Shijie. Effects of chemotherapy dose intensity on short-term efficacy in patients with advanced colon cancer： a study based on real-world data [J]. Journal of International Oncology, 2022, 49(7): 408-415.
[8]	Tang Lin, Xiang Mingyue, Zhang Jianbo, Wang Lili, Gong Heyi, Han Dali. Clinical efficacy and safety of camrelizumab combined with apatinib and chemotherapy as second-line or later therapy in the treatment of HER-2 negative advanced gastric cancer [J]. Journal of International Oncology, 2022, 49(5): 276-281.
[9]	Gao Shile, Lu Donghui, Liu Meiqin, Xu Xingjun, Ma Huan, Zhang Yu. Clinical efficacy and optimal dose of apatinib combined with chemotherapy in patients with advanced non-small cell lung cancer [J]. Journal of International Oncology, 2022, 49(3): 140-145.
[10]	Lao Zheng, Tu Wenyong, Xu Xuanli, Zhang Lin, Shao Ziyang, Shi Huifeng. Nimotuzumab combined with definitive radiotherapy for inoperable locally advanced oral and maxillofacial squamous cell carcinoma [J]. Journal of International Oncology, 2022, 49(11): 665-670.
[11]	Luo Liyun, Lai Canhui, Liang Renpei, Yang Aiwu, Lin Zhimin. Correlation between the expressions of miR-524-5p and SOX9 in advanced gastric cancer and their influences on chemotherapy efficacy and prognosis [J]. Journal of International Oncology, 2022, 49(1): 45-50.
[12]	Long Xin, Wu Han, Peng Jin, Zhou Fuxiang. Systemic therapy of advanced biliary tract cancer [J]. Journal of International Oncology, 2021, 48(5): 302-307.
[13]	Song Yang, Wang Bin, Xiao He, Chen Chuan, Wang Ge, Geng Mingying. Predictive value of tumor regression rate after induction chemotherapy for survival of patients with locally advanced nasopharyngeal carcinoma [J]. Journal of International Oncology, 2021, 48(3): 156-163.
[14]	Chi Xiuying, Wang Hongbiao, Li Zhifeng, Lin Yingcheng. Progression in the therapies of relapse or metastatic esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2021, 48(12): 755-759.
[15]	Wang Xuan, Cui Lichun, Dang Shengqiang. Effects of apatinib combined with chemoradiotherapy on the efficacy and tumor markers of advanced gastric cancer [J]. Journal of International Oncology, 2021, 48(10): 602-607.